Kidney response rates from the study after 12 months are expected in the first half of 2013. A separate phase III study investigating the combination of Amigal and Fabrazyme, an currently approved therapy for Fabry disease from the Genzyme unit of Sanofi ( SNY), will report results in 2014.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Remember, Fed News Is a Trigger for the Computers

Strong Action in Individual Stocks Starts to Feel a Bit Frothy

The Flippers Are at Work and the Bears Are Hopeful

Portola Shares Lower After Pricing Stock Offering - Biotech Movers

Time to Bring Amicus Therapeutics Into the 'FOLD'